Telesso Technologies Limited (ASX: TEO), a global healthcare company,
announced today that Miami Children’s hospital is the first site to
enroll patients in a head-to-head trial evaluating its FDA-approved
guide wire-assisted peripheral IV catheter versus the industry’s gold
standard device for peripheral IV placement. Telesso is funding the
catheter clinical trial with Vascular Pathways, Inc.
“This post-market study represents the advancement of an important
innovation in medicine designed to reduce the safety risks and costs
traditionally associated with peripheral IV catheter use,” said
Telesso’s CEO Nelson Stacks. “We are encouraged by the interest and
positive feedback Telesso has received to date, and we look forward to
announcing additional sites shortly with data review in Q2-Q3 of this
year.”
The trial will enroll approximately 400 pediatric, geriatric and
oncology patients at three world-class sites who will be treated with
either the novel guide-wire assisted peripheral IV catheter or the
current standard of care.
About the Guide Wire-Assisted Peripheral IV Catheter
A peripheral vein is the most common site for insertion of a catheter
for short-term diagnostic or therapeutic use. The catheter is placed
into the peripheral vein in the arm, below the elbow and is typically
passed up inside the vein to a length of 2-3 inches. Telesso’s
uniquely-designed guide wire-assisted peripheral IV catheter device uses
a first-in-class retractable nitinol guide wire system that is believed
to enable easier IV access, reduce common safety risks, significantly
lessen patient pain and discomfort, and provide cost savings to
facilities by lowering administrative costs associated with failed IV
starts. Telesso believes this catheter device is the first clinically
meaningful advancement in peripheral IV access since automatic needle
retraction catheters and addresses significant unmet needs in peripheral
intravenous access.
About the Telesso-VPI Agreement
Telesso Technologies Limited announced in December 2008 that it entered
into a strategic agreement with Vascular Pathways, Inc. (VPI), a private
company based in California, to co-develop VPI’s guide wire-assisted
device with the funding of the clinical trial and to potentially acquire
VPI.
For more information, visit Telesso’s web site at http://www.telesso.com.
Telesso Technologies
Ian Atkin, Chief Financial Officer, Australia
+61
2 9805 0022
or
Jeff Riley, President, USA
+1.619.309.7661
